Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 8Glioblastoma 8Astrocytoma 7Brain Neoplasms 5Central Nervous System Neoplasms 3Recurrence 2Gliosarcoma 2Oligodendroglioma 1Neoplasms 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × IL13-PE38 × Clear all
NCT00024570 2014-11-14

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Completed
60 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

NCT00024557 2011-06-06

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

INSYS Therapeutics Inc

Phase 1 Completed
40 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡